The remarkable global development of disease-modifying therapies (DMTs) specific for multiple sclerosis (MS) has signifi cantly reduced the frequency of relapse, slowed the progression of disability, and improved the quality of life in patients with MS. With increasing numbers of approved DMTs, neurologists in North America and Europe are able to present multiple treatment options to their patients to achieve a better therapeutic outcome, and in many cases, no evidence of disease activity. MS patients have improved accessibility to various DMTs at no or minimal out-of-pocket cost. The ethical guidelines defi ned by the Edinburgh revision of the Declaration of Helsinki strongly discourage the use of placebo control groups in modern MS clinical trials. The use of an active comparator control group increases the number of participants in each group that is essential to achieve statistical signifi cance, thus further increasing the diffi culty of completing randomized controlled trials (RCTs) for the development of new MS therapies. There is evidence of a high prevalence of MS and a large number of patients in Asia. The belief of the existence of Asian types of MS that are distinct from Western types, and regulatory policies are among the reasons why DMTs are limited in most Asian countries. Lack of access to approved DMTs provides a good opportunity for clinical trials that are designed for the development of new MS therapies. Recently, data from RCTs have demonstrated excellent recruitment of participants and the completion of multi-nation and single-nation MS trials within this region. Recent studies using the McDonald MS diagnostic criteria carefully excluded patients with neuromyelitis optica (NMO) and NMO spectrum disorder, and demonstrated that patients with MS in Asia have clinical characteristics and treatment responses similar to those in Western countries.
Introduction
Evidence-based medicine scrutinizes treatment initiatives, establishes a scientific basis for the use of medications, and assesses the appropriateness of tests. Evidencebased practice (EBP) with standardized protocols and guidelines is increasingly used by healthcare professionals in the diagnosis and treatment of various disorders including multiple sclerosis (MS) [1, 2] . EBP enhances the quality of medical practice by improving outcomes, optimizing resources, and minimizing risks. In contrast to practicing medicine according to personal beliefs that are not tested by evidence of benefits outweighing risks, EBP uses the best evidence to make clinical decisions for individual patients. Several steps are involved in EBP.
Immediately following the fi rst step of identifying question(s)
for individual patients, healthcare professionals retrieve the information necessary to answer the questions. Data from blind randomized controlled trials (RCTs) are considered the strongest evidence for reliable information. When designed and carried out appropriately, RCTs are accepted as class I evidence. Well-designed and executed RCTs include technical elements such as randomization, placebo control, blinding, allocation concealment to adequately control bias caused by selection or unknown confounders, placebo effects, and co-interventions [3] . Data from RCTs are required for pharmaceutical companies to gain approvals from regulatory authorities in various countries and regions.
The currently available disease-specific therapies for MS are known to modify the disease activity by reducing relapses and slowing the progression of disability, and to be partially effective in treating the relapsing form of MS.
New therapies are being tested via RCTs and seem to have potent clinical and radiographic efficacy compared to the current approved therapies. In addition to a better therapeutic outcome, these new therapies have improved side-effect profiles and/or offer the convenience of oral administration [4] [5] [6] .
Approved Disease-Modifying Therapies (DMTs) and Emerging Therapies
The global development of therapies for MS has been very successful for the last 2 decades. The therapeutic 
First-Line Basic Therapeutics
Interferon preparations (Avonex®, Betaseron®/Betaferon®, Extavia®, Rebif®, and Plegridy®) and glatiramer acetate The relatively newer oral agents can be used as fi rstline basic DMTs or second-line escalation therapeutics.
Fingolimod [8, 9] (Gilenya®), a sphingosine- [4, 14] (Tecfi dera®) is another oral DMT for relapsing forms of MS. 
Second-Line Escalation Therapeutics
Agents in this category are usually more potent than the first-line basic DMTs. Natalizumab [15, 16] 18 (1) 116 (9) 107 (8) 171 (11) NR NR Caucasian 278 (92) 166 (86) 899 (95) 1313 (95) 1216 (94) 969 (79) 1191 (84) 1237 (82) 532 (92) 714 (85) African American 20 (7) 15 (8) 10 (1) 3 (0) 16 (1) 26 (2) 27 (2) 7 ( 12 (6) 27 (3) 50 (4) 39 (3) 123 (10) 92 (6) 97 (6) 49 (8) development of new treatment options for MS, recent years have witnessed increasing difficulties and obstacles to complete RCTs in a timely and cost-effective manner.
Ethical Issues in Human Research: The Revision of the Declaration of Helsinki
In the Edinburgh (2000) revision of the Declaration of Helsinki [20, 21] towards the "middle ground" [22] .
Placebo responded to the established therapy [23] .
Challenges in RCTs for MS
With the increased number of DMTs and their signifi cantly improved availability to the general population in the USA, Canada, the European Union, and many other countries, we have witnessed increasing challenges in the enrollment of participants into various RCTs for MS therapies. The SURPASS trial was a multicenter, randomized, raterblind, parallel-group, active-controlled study to evaluate the benefits of switching therapy (glatiramer acetate or interferon-1) to natalizumab in participants with RR-MS.
Due to slow enrollment and other issues, the SURPASS trial was terminated prematurely. The elimination of placebo controls, and comparison between the trial agent and an approved therapy, signifi cantly increases (usually by >10×) the number of participants required to achieve statistical difference. Often, the original trial protocols have to be amended and the projected enrollment timelines extended.
Due to the difficulties in enrollment, one of the two anti-CD52 antibody treatment groups in the CARE MS II trial was eliminated during the enrollment period [17] . ASSESS 
Strategies for Effectively Completing RCTs of MS
A few recently-completed RCTs changed the traditional approach in their enrollment strategies. In contrast to limiting participants exclusively to Western countries (Table   3 ), these RCTs included MS patients from other regions such as Asia. A total of 9%, 10%, and 11% of participants were recruited from Asian populations in the DEFINE, CONFIRM, and ADVANCE trials [4, 14, 24] .
Dimethyl fumarate ( (Table 4) . Of note, the total numbers of Asian patients in all treatment groups and placebo groups were higher than those of African American patients, but lower than those of Caucasian patients.
Distinct Features of Multiple Sclerosis in Asian Countries
Despite the discovery of anti-aquaporin-4 antibody in patients with neuromyelitis optica (NMO) and the establishment of NMO as a separate disease entity [25, 26] , the belief that Asian MS has unique features compared with the conventional MS in western countries continues to be common in MS research and neurology practice. The relatively high prevalence of opticospinal MS (OSMS) [27] ( Fig. 1A, B [28] . Moreover, most of the studies used the 1983 Poser diagnostic criteria for MS and/or were based on hospitalized patients. Historically, it was believed that the prevalence of MS in Eastern Asia was 1-2 cases per 100 000 population. With multiple revisions of the diagnostic criteria, the improved availability of neurologists, and the increased use of MRI in the diagnosis of CNS (7) 11 (3) 13 (4) 11 ( population in northern Japan [29, 30] . The prevalence of MS in Western Asia and the Middle East (including Kuwait, Israel, Turkey, Jordan, and Iraq) is believed to be higher than that in other parts of Asia, while Southern Asian countries such as India, Pakistan, Bangladesh, Sri Lanka, Nepal have a low rate of MS prevalence [31] . Of note, the DEFINE, CONFIRM, and ADVANCE trials were able to recruit a fairly good number of patients in India.
Asian-type versus Conventional-type Multiple

Sclerosis and Responsiveness to DMTs
It is challenging to conduct RCTs in countries where the disease has a high degree of heterogeneity. It is vital to understand the heterogeneity from various aspects, including clinical phenotype, MRI features, and immunological abnormalities. It is well known that AfricanAmericans tend to have a high frequency of clinical MS relapses and a poor long-term prognosis [32] . Patients with cervical spinal cord lesions tend to have Expanded Disability Status Scale progression and develop disability earlier and faster. A signifi cant percentage of MS patients may harbor genetic variations, and possess distinct pretreatment immunologic profi les that render a given DMT ineffective [33] .
The perception of more common or a relatively higher prevalence of OSMS in Asia might be attributable to the lack of epidemiologic data on MS and the disproportionate (Fig. 2) .
Over the last 2 decades, significant improvements have been made in the diagnosis and differential diagnosis of NMO/NMO spectrum disorder (NMOSD) [34] and MS. The After careful exclusion of patients with NMOSD, a cohort of 105 Korean patients with MS were not fundamentally different from MS patients in Western countries [35] . The 2005 and 2010 McDonald MS diagnostic criteria were used in this study. In addition, the following patients were excluded: (1) patients with NMO, as in a recent RCT [36, 37] . A post-hoc analysis was performed to explore the efficacy of dimethyl fumarate (Tecfidera®) in minority populations including patients of African, Hispanic, and Asian descent. A trend favoring Tecfidera® was reported in all 3 of these populations. However, the variability of the clinical responses and small sample sizes contributed to the statistically non-significant outcome.
Further investigations in these groups are warranted. As MS remains underdiagnosed in many parts of Asia, and given the lack of epidemiological data, the size of the Asian market for DMTs for the treatment of MS is unknown. However, given its enormous population, the rapid rise of its economic power, improved living standards, access to health insurance, and the advancement of neurological specialty care in Asia [38] , the importance of such an emerging market cannot be overestimated. Some 
MS Trials in Asian Countries
